Physician profile
Umesh Verma
NPI 1891751806
$9,077.24
in general payments reported to CMS, 2019-2025
45 companies · $1,743 in 2025
The $1,743 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,606 · 2020: $1,659 · 2021: $1,474 · 2022: $59.30 · 2023: $1,365 · 2024: $1,171 · 2025: $1,743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,278.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $1,181.02 | 2019-2025 | Mavenclad |
| Ucb, INC. | $940.79 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Biogen, INC. | $864.34 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Teva Pharmaceuticals USA, INC. | $791.38 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $547.48 | 2019-2021 | |
| Abbvie INC. | $508.79 | 2019-2025 | Qulipta |
| Novartis Pharmaceuticals Corporation | $340.37 | 2019-2025 | |
| Eisai INC. | $335.29 | 2020-2025 | |
| Genentech USA, INC. | $291.20 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Lundbeck LLC | $290.56 | 2020-2025 | Vyepti |
| Neurocrine Biosciences, INC. | $269.10 | 2019-2025 | Ingrezza, Ongentys |
| Amgen INC. | $257.02 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $213.40 | 2019-2021 | |
| Pfizer INC. | $200.47 | 2023-2025 | |
| Lilly USA, LLC | $187.87 | 2019-2025 | Kisunla, Amyvid, Emgality |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umesh Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.